Benefits of Adjuvant Radiation in DCIS Persist Out to 15 Years
Adjuvant radiation therapy (RT) for good-risk ductal carcinoma in situ (DCIS) reduced long-term ipsilateral breast recurrence (IBR) by more than 50% compared with observation, results of a large intergroup study showed. RT, following surgery with or without tamoxifen, decreased 15-year IBR from 15.1% with observation to 7.1%. RT also reduced the odds of invasive local […]
PD-1 Inhibitor OK’d as Adjuvant Therapy for Bladder Cancer
The FDA has approved nivolumab (Opdivo) as an adjuvant therapy for patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection, regardless of prior neoadjuvant chemotherapy, nodal involvement, or PD-L1 status, Bristol Myers Squibb announced. Nivolumab becomes the first PD-1 inhibitor in UC with an indication in the adjuvant […]
Breast Cancer Control Similar With Intermittent, Continuous Endocrine Therapy
Intermittent or continuous extended adjuvant endocrine therapy led to virtually identical long-term survival in hormone receptor (HR)-positive breast cancer, according to an updated analysis of a randomized trial. Disease-free survival (DFS) at 7 years was 81.4% with intermittent extended letrozole and 81.5% with continuous treatment. The results mirrored previously reported 5-year DFS, which also did […]